Raj Kumar Chohan, Ghulam Mustafa Dahri, Shah Murad, Anser Asrar, Anis Fatima.
Role of pioglitazone and glibenclamide in type 2 diabetes mellitus (NIDDM) patients.
Pak J Med Health Sci Jan ;4(4):508-11.

Objective: Study was planned to examine and compare the effects of oral antidiabetic drugs in Type 2 Diabetes Mellitus patients. Design: Prospective and comparative study Place and duration of study: Study was conducted at the department of Pharmacology, Basic Medical Sciences Institute (BMSI) in collaboration with Medical Department Jinnah Post-graduate Medical Centre (JPMC) Karachi, from january 2006 to July 2006. Patients and methods: Sixty newly untreated Type 2 Diabetes Mellitus patients were enrolled in the study. Females and Males patients were divided in two groups. In group I patients (n=27) were treated with drug pioglitazone 15 mg after meal. In group II (n=33) patients were treated with drug glibenclamide 5mg early morning just before break fast. Both drugs were given for over all study period. No titration of dose was needed. Patients with peptic ulcer, renal diseases ,hepatic diseases ,blood disease, any serious complications were excluded from the study .General Physical examination, pulse, blood pressure, routine investigation, etc recorded at the time of patients enrolment and same assessments taken on day 45 and day 90. Fasting Blood Sugar ,and Random Blood Sugar was calculated by` Glucose-Oxidase `Enzymatic Method. Procedure was explained to patients and written consent was obtained on Proforma especially designed for research. Data were expressed as the Mean±SEM at the end of study and was analysis by paired `t` test. Results: Out of 70 type 2 Diabetes Mellitus patients 60 patients were completed over all study period. Two patients withdrew from one group; i.e. drug glibenclamid group due to adverse effects like hypoglycemia .Difference between two groups at the end of study shows better results in parameters .In parameter FBS At day-0 mean value was 188.42±12.05 mg/dl At Day 45 168.45±10.99 mg/dl At Day 90 140.06±5.68 mg/dl. P Value from day-0 to day-90 was <0.05* which was significant In parameter RBS At Day-0 mean value was 284.18± 17.03 mg/dl At Day-45 220.12±13.39 At Day-90 170.94±5.80 mg/dl. P Value from day-0 to day-45 was <0.005** which is moderately significant and from day-45 to day-90 P value was <0.002** which is also moderately significant result in group II with drug glibenclamide. Conclusion: Finally we concluded from this study that drug glibenclamide controlled Type 2 Diabetes Mellitus by decreasing blood sugar level in a given study period as compared with other study drug, pioglitazone.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com